Michael Raymond Collins

This inventor holds 21 USPTO granted patents and 10 published patent applications, plus 7 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Pfizer Corporation, Agouron Pharmaceuticals, Inc., Iteos Therapeutics. Active years: 2003-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Raymond Collins. Retrieved from https://idiyas.com/inventor/michael-raymond-collins

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 10)

% Patents Active = 71.4

CIPO Patents = 7 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 5.4

ph-index = 9

Forward Citations = 624(Granted Patents)

Location History:

Bedford, NH (US) (2008 - 2009)
San Diego, CA (US) (2003 - 2020)

Company Filing History:

Agouron Pharmaceuticals, Inc.

4. 2 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2020

Loading Chart...

Areas of Expertise:

Cycloalkyl-Linked Derivatives

Anticancer Agents

Protein Kinase Inhibitors

Macrocyclic Derivatives

Dihydroisoquinolinone Compounds

Quinazoline Derivatives

Thienopyridines

Pharmaceutical Compositions

Indazole Compounds

3-Indol Substituted Derivatives

CHK-1 Inhibitors

Axl Inhibitors

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10676471 - Cycloalkyl-linked diheterocycle derivatives (2020-06-09),

2. 10662204 - Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents (2020-05-26),

3. 10590115 - Tetrahydroquinazoline derivatives useful as anticancer agents (2020-03-17),

4. 10570121 - Substituted dihydroisoquinolinone compounds (2020-02-25),

5. 10544095 - 3-indol substituted derivatives, pharmaceutical compositions and methods for use (2020-01-28),

6. 10125130 - Cycloalkyl-linked diheterocycle derivatives (2018-11-13),

7. 9873690 - 3-indol substituted derivatives, pharmaceutical compositions and methods for use (2018-01-23),

8. 9593097 - Axl inhibitors (2017-03-14),

9. 9133215 - Macrocyclic derivatives for the treatment of diseases (2015-09-15),

10. 8680111 - Macrocyclic derivatives for the treatment of diseases (2014-03-25),

11. 8518952 - 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors (2013-08-27),

12. 7565764 - Insect collector and viewer (2009-07-28),

13. 7404269 - Insect collector and viewer (2008-07-29),

14. 7141587 - Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use (2006-11-28),

15. 7045528 - Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use (2006-05-16),

Title: The Innovative Genius of Michael Raymond Collins

Introduction

Michael Raymond Collins, an esteemed inventor based in San Diego, CA, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio consisting of 19 patents, Collins has focused his research efforts on developing compounds that are instrumental in combating various forms of cancer.

Latest Patents

Among his latest inventions are groundbreaking patents such as "Cycloalkyl-linked diheterocycle derivatives." This invention encompasses compounds that have shown potential in provided innovative solutions to medical challenges. Another notable patent involves "Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents," which details the preparation and application of compounds designed to treat pancreatic, lung, colon, and other cancers. These contributions highlight Collins’ dedication to advancing cancer therapies.

Career Highlights

Collins has had a prolific career working with prominent companies in the pharmaceutical sector. He has collaborated with Pfizer Corporation and Agouron Pharmaceuticals, Inc., where his work significantly contributed to drug development processes. His commitment to innovation in medicine has earned him respect and recognition among his peers.

Collaborations

Throughout his career, Collins has had the privilege of working alongside talented colleagues, including Robert Steven Kania and Cynthia Louise Palmer. These collaborations have allowed him to expand his knowledge and amplify the impact of his inventions in the field.

Conclusion

Michael Raymond Collins stands out as an accomplished inventor whose contributions, particularly in cancer research, are invaluable. His patents are a testament to his innovative spirit and dedication to improving patient outcomes. With a solid foundation in the pharmaceutical industry, Collins continues to inspire future generations of inventors and researchers through his work.

Profile summary based on public USPTO records.